- Raw materials
- Antibacterials
- Friulimicin B
Friulimicin B API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Friulimicin B | CAS No: 239802-15-4 | GMP-certified suppliers
A medication that addresses bacterial infections by targeting Gram-positive pathogens with a novel mechanism, currently under investigation for therapeutic use.
Therapeutic categories
Primary indications
- Investigated for use/treatment in bacterial infection
Product Snapshot
- Friulimicin B is a peptide antibiotic formulated for injectable use
- It is primarily investigated for the treatment of bacterial infections
- The compound remains in the investigational phase and is not yet approved by major regulatory agencies
Clinical Overview
This compound demonstrates potent bactericidal activity against a range of Gram-positive pathogens. These organisms frequently contribute to serious infections in hospitalized patients and have an increasing incidence in community-acquired settings. The unique mechanism of action of Friulimicin B distinguishes it from other antibiotics in clinical use. In the presence of calcium ions, Friulimicin B forms a complex with a specific lipid carrier involved in bacterial cell wall biosynthesis. By interfering with this lipid carrier, the drug disrupts two essential pathways within the bacterial cell envelope, ultimately preventing the construction of a functional cell wall. This mode of action targets pathways not affected by currently available antibiotics.
Detailed pharmacokinetic data, including absorption, distribution, metabolism, and excretion parameters, are not widely reported, reflecting its investigational status. Safety and toxicity profiles remain under evaluation, with limited clinical exposure to date informing tolerability and potential adverse effects. Friulimicin B has not received regulatory approval and is not marketed under any commercial brand names.
Given the novel mechanism and investigational status, sourcing active pharmaceutical ingredient (API) for Friulimicin B requires stringent quality control measures. Production involves cultivation of Actinoplanes friuliensis under controlled fermentation conditions, followed by complex purification processes. For formulation development and regulatory submission, comprehensive characterization of API purity, identity, and stability is essential to meet global pharmaceutical standards.
Identification & chemistry
| Generic name | Friulimicin B |
|---|---|
| Molecule type | Small molecule |
| CAS | 239802-15-4 |
| UNII | AYO43961I1 |
| DrugBank ID | DB06087 |
Pharmacology
| Summary | Friulimicin B is a calcium-dependent antibiotic that targets bacterial cell wall biosynthesis by forming complexes with lipid carriers distinct from those affected by other antibiotics. Its mechanism involves simultaneous inhibition of two essential pathways in the bacterial cell envelope, leading to disruption of functional cell wall formation. This dual-action profile is under investigation for the treatment of bacterial infections. |
|---|---|
| Mechanism of action | Friulimicin B, in the presence of calcium, forms a complex with a lipid carrier that acts in cell wall biosynthesis and which is not targeted by other antibiotics currently in use. Friulimicin B appears to block two essential pathways in the cell envelope and the complexes formed prevent the formation of a functional cell wall. |
Formulation & handling
- Friulimicin B is a small molecule oligopeptide with low water solubility, requiring careful formulation to enhance bioavailability for oral or parenteral administration. Due to its peptide nature and low LogP, it may exhibit limited membrane permeability, impacting absorption and distribution profiles. Handling should consider potential sensitivity to enzymatic degradation and maintain stability under controlled temperature and pH conditions.
Regulatory status
Friulimicin B is a type of Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
